Henning T. Mouridsen

Author

Also Known As

H MOURIDSEN, H Mouridsen, H T Mouridsen, H. Mouridsen, H. T. Mouridsen, H.T Mouridsen, H.T. MOURIDSEN, H.T. Mouridsen, Henning Mouridsen, Henning T Mouridsen

305

Publications

20.6K

Citations

H-Index

119

Concepts

All Affiliations

Rigshospitalet Danish Breast Cancer Cooperative Group Copenhagen University Hospital Herlev Hospital Odense University Hospital

About

Henning T. Mouridsen is an author at Rigshospitalet specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	89	8.1K
2	Health Sciences	11	13	2.4K
3	Public Health	6	6	526
4	Nursing	5	5	472
5	Engineering	1	1	18

Henning T. Mouridsen

155

Publications

17.9K

Citations

H-Index

Page 1

	Year	Citations
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy Marie Overgaard, Per Syrak Hansen, Jens Overgaard, New England Journal of Medicine	1997	2.6K
Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial Marie Overgaard, Maj‐Britt Jensen, Jens Overgaard, The Lancet Breast OncologyRadiation TherapyMedicineCancer ManagementAdjuvant Tamoxifen	1999	1.6K
Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group Henning T. Mouridsen, Mikhail Gershanovich, Yan Sun, Journal of Clinical Oncology	2001	1K
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98 Alan S. Coates, Aparna Keshaviah, Beat Thürlimann, Journal of Clinical Oncology	2007	897
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study M. van Glabbeke, A.T. van Oosterom, J. Wolter Oosterhuis, Journal of Clinical Oncology	1999	565
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Armando Santoro, T Türsz, Henning T. Mouridsen, Journal of Clinical Oncology	1995	526
Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients Mogens Grøenvold, Morten Aagaard Petersen, Ellen Idler, Breast Cancer Research and Treatment Fatigue ManagementPsychiatryStressDepressionBreast Cancer	2007	366
Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial Per Soelberg Sørensen, S. Helweg‐Larsen, Henning T. Mouridsen, European Journal of Cancer Neuro-oncologySpinal Cord InjuryRadiation TherapyMedicineRandomised Trial	1994	348
Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative Group Ann Knoop, Helle Knudsen, Eva Balslev, Journal of Clinical Oncology	2005	323
Long-term results of breast conserving surgery vs. mastectomy for early stage invasive breast cancer: 20-year follow-up of the Danish randomized DBCG-82TM protocol M Blichert-Toft, Maja Nielsen, Maria Düring, Acta Oncologica Surgical OncologyInvasive Breast CarcinomaBreast OncologyMedicineBreast Conserving Surgery	2008	294

Page 1